1. Home
  2. DCTH vs TCI Comparison

DCTH vs TCI Comparison

Compare DCTH & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • TCI
  • Stock Information
  • Founded
  • DCTH 1988
  • TCI 1983
  • Country
  • DCTH United States
  • TCI United States
  • Employees
  • DCTH N/A
  • TCI N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • TCI Real Estate
  • Sector
  • DCTH Health Care
  • TCI Finance
  • Exchange
  • DCTH Nasdaq
  • TCI Nasdaq
  • Market Cap
  • DCTH 388.3M
  • TCI 357.8M
  • IPO Year
  • DCTH N/A
  • TCI N/A
  • Fundamental
  • Price
  • DCTH $11.75
  • TCI $46.09
  • Analyst Decision
  • DCTH Strong Buy
  • TCI
  • Analyst Count
  • DCTH 4
  • TCI 0
  • Target Price
  • DCTH $24.50
  • TCI N/A
  • AVG Volume (30 Days)
  • DCTH 497.8K
  • TCI 1.5K
  • Earning Date
  • DCTH 11-07-2025
  • TCI 11-06-2025
  • Dividend Yield
  • DCTH N/A
  • TCI N/A
  • EPS Growth
  • DCTH N/A
  • TCI 11.20
  • EPS
  • DCTH 0.06
  • TCI 0.76
  • Revenue
  • DCTH $70,240,000.00
  • TCI $47,730,000.00
  • Revenue This Year
  • DCTH $159.22
  • TCI N/A
  • Revenue Next Year
  • DCTH $42.78
  • TCI N/A
  • P/E Ratio
  • DCTH $211.26
  • TCI $59.65
  • Revenue Growth
  • DCTH 491.35
  • TCI N/A
  • 52 Week Low
  • DCTH $8.08
  • TCI $25.50
  • 52 Week High
  • DCTH $18.23
  • TCI $48.00
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 59.13
  • TCI 52.60
  • Support Level
  • DCTH $10.61
  • TCI $44.20
  • Resistance Level
  • DCTH $11.38
  • TCI $46.50
  • Average True Range (ATR)
  • DCTH 0.49
  • TCI 0.71
  • MACD
  • DCTH 0.06
  • TCI -0.26
  • Stochastic Oscillator
  • DCTH 79.61
  • TCI 64.07

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: